A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

被引：1

作者：

van Not, Olivier J. ^{[1
,2
]}

Wind, Thijs T. ^{[3
]}

Ismail, Rawa K. ^{[1
]}

Bhattacharya, Arkajyoti ^{[3
]}

Jalving, Mathilde ^{[3
]}

Blank, Christian U. ^{[4
,5
]}

Aarts, Maureen J. B. ^{[6
]}

van den Berkmortel, Franchette W. P. J. ^{[7
]}

Boers-Sonderen, Marye J. ^{[8
]}

van den Eertwegh, Alfonsus J. M. ^{[9
]}

de Groot, Jan Willem B. ^{[10
]}

Haanen, John B. ^{[4
]}

Kapiteijn, Ellen ^{[11
]}

Bloem, Manja ^{[1
,12
,13
]}

Piersma, Djura ^{[14
]}

van Rijn, Rozemarijn S. ^{[15
]}

Stevense-den Boer, Marion ^{[16
]}

van der Veldt, Astrid A. M. ^{[17
]}

Vreugdenhil, Gerard ^{[18
]}

Wouters, Michel W. J. M. ^{[1
,12
,13
]}

Blokx, Willeke A. M. ^{[19
]}

Suijkerbuijk, Karijn P. M. ^{[2
]}

Fehrmann, Rudolf S. N. ^{[3
]}

Hospers, Geke A. P. ^{[3
]}

机构：

[1] Dutch Inst Clin Auditing, Sci Bur, Rijnsburgerweg 10, NL-2333 AA Leiden, Netherlands

[2] Univ Med Ctr Utrecht, Dept Med Oncol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

[3] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands

[4] Netherlands Canc Inst, Dept Mol Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

[5] Netherlands Canc Inst, Dept Med Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

[6] Maastricht Univ, GROW Sch Oncol & Reprod, Dept Med Oncol, Med Ctr, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands

[7] Zuyderland Med Ctr Sittard, Dept Med Oncol, Dr H van der Hoffplein 1, NL-6162 BG Geleen, Netherlands

[8] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Geert Grooteplein Zuid 10, NL-6525 GA Nijmegen, Netherlands

[9] Vrije Univ Amsterdam Med Ctr, Amsterdam UMC, Canc Ctr Amsterdam, Dept Med Oncol, De Boelelaan 1118, NL-1081 HZ Amsterdam, Netherlands

[10] Isala Oncol Ctr, Dept Med Oncol, Dokter van Heesweg 2, NL-8025 AB Zwolle, Netherlands

[11] Leiden Univ, Med Ctr, Dept Med Oncol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands

[12] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Einthovenweg 20, NL-2333 ZC Leiden, Netherlands

[13] Netherlands Canc Inst, Dept Surg Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

[14] Med Spectrum Twente, Dept Internal Med, Koningspl 1, NL-7512 KZ Enschede, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Henri Dunantweg 2, NL-8934 AD Leeuwarden, Netherlands

[16] Amphia Hosp, Dept Internal Med, Molengracht 21, NL-4818 CK Breda, Netherlands

[17] Erasmus MC, Dept Med Oncol & Radiol & Nucl Med, S-Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands

[18] Maxima Med Ctr, Dept Internal Med, Run 4600, NL-5504 DB Eindhoven, Netherlands

[19] Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

来源：

CANCERS | 2023年 / 15卷 / 11期

关键词：

advanced melanoma; immunotherapy; brain metastases; survival tree; ANTI-PD-1; THERAPY; SYSTEMIC THERAPY; SURVEILLANCE; PROGNOSIS;

D O I：

10.3390/cancers15112922

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any line between 2013 and 2020 were obtained from the Dutch Melanoma Treatment Registry. Patients were included from the time of the treatment of BM with ICIs. Survival tree analysis was performed with clinicopathological parameters as potential classifiers and overall survival (OS) as the response variable. In total, 1278 patients were included. Most patients were treated with ipilimumab-nivolumab combination therapy (45%). The survival tree analysis resulted in 31 subgroups. The median OS ranged from 2.7 months to 35.7 months. The strongest clinical parameter associated with survival in advanced melanoma patients with BM was the serum lactate dehydrogenase (LDH) level. Patients with elevated LDH levels and symptomatic BM had the worst prognosis. The clinicopathological classifiers identified in this study can contribute to optimizing clinical studies and can aid doctors in giving an indication of the patients' survival based on their baseline and disease characteristics.

引用

页数：12

共 50 条

[1] MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors
Bhatia, Ankush
Birger, Maxwell
Veeraraghavan, Harini
Um, Hyemin
Tixier, Florent
McKenney, Anna Sophia
Cugliari, Marina
Caviasco, Annalise
Bialczak, Angelica
Malani, Rachna
Flynn, Jessica
Zhang, Zhigang
Yang, T. Jonathan
Santomasso, Bianca D.
Shoushtari, Alexander N.
Young, Robert J.
NEURO-ONCOLOGY, 2019, 21 (12) : 1578 - 1586
[2] Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Lee, Jenny H.
Menzies, Alexander M.
Carlino, Matteo S.
McEvoy, Ashleigh C.
Sandhu, Shahneen
Weppler, Alison M.
Diefenbach, Russell J.
Dawson, Sarah-Jane
Kefford, Richard F.
Millward, Michael J.
Al-Ogaili, Zeyad
Tra, Thien
Gray, Elin S.
Wong, Stephen Q.
Scolyer, Richard A.
Long, Georgina, V
Rizos, Helen
CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4064 - 4071
[3] Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)
Ribeiro, M. F. Silva Almeida
Muniz, T. Pimentel
Jablonska, P.
Hirsch, I.
Vilbert, M.
Koch, E. C.
Mantle, L.
Saibil, S.
Spreafico, A.
Hogg, D.
Shultz, D.
Butler, M. O.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S930 - S930
[4] Improved Outcomes in Patients with Melanoma Brain Metastases Treated with Whole-Brain Radiation and Immune Checkpoint Inhibitors
Cannon, D. M.
Burt, L. M., Jr.
Voorhies, B. N.
Hitchcock, Y. J.
Shrieve, D. C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E72 - E72
[5] Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Spillane, Susan
Baxi, Shrujal
Torres, Aracelis Z.
Lenis, David
Freedman, Andrew N.
Mariotto, Angela B.
Sharon, Elad
ONCOLOGIST, 2020, 25 (11): : E1753 - E1762
[6] Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma
Tenstad, H. B.
Ruhlmann, C. H.
Moller, S.
Kjaer, S.
Bastholt, L.
Just, S. A.
Lindegaard, H.
JOURNAL OF AUTOIMMUNITY, 2025, 152
[7] PREVALENCE OF RHEUMATIC TOXICITIES IN PATIENTS WITH ADVANCED MELANOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Bruce, Alana
Long, Georgina
Menzies, Alexander
Fernandes, Brian
Joshua, Fredrick
INTERNAL MEDICINE JOURNAL, 2020, 50 : 37 - 38
[8] Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
Elkrief, Arielle
El Raichani, Layal
Richard, Corentin
Messaoudene, Meriem
Belkaid, Wiam
Malo, Julie
Belanger, Karl
Miller, Wilson
Jamal, Rahima
Letarte, Nathalie
Wong, Philip
Routy, Bertrand
ONCOIMMUNOLOGY, 2019, 8 (04):
[9] Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
Mantia, Charlene M. M.
Werner, Lillian
Stwalley, Brian
Ritchings, Corey
Tarhini, Ahmad A. A.
Atkins, Michael B. B.
McDermott, David F. F.
Regan, Meredith M. M.
MELANOMA RESEARCH, 2022, 32 (01) : 35 - 44
[10] Immune Prognostic Index as a predictor of survival in patients with metastatic melanoma treated with immune checkpoint inhibitors
Stukalin, Igor
Suo, Aleksi
Vallerand, Isabelle A.
Lewinson, Ryan
Heng, Daniel Y. C.
Bebb, D. Gwyn
Morris, Don G.
Cheng, Tina
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB100 - AB100

← 1 2 3 4 5 →